Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Pruritus is a complication of chronic kidney disease (CKD) and is one of the most distressing symptoms experienced by patients undergoing hemodialysis (HD), significantly affecting their quality of life. This symptom is often underdiagnosed in HD centers, in up to 65% of cases, which prevents comprehensive patient care. It is necessary to determine the prevalence and characteristics of this symptom in the Mexican population and its impact on quality of life, in order to develop a comprehensive management protocol.
An observational, cross-sectional, and descriptive study was conducted. We studied 200 HD patients at the Regional Center for Kidney Diseases (CRER) to estimate the prevalence of pruritus. Results of complete blood count, creatinine levels, blood urea nitrogen (BUN), serum electrolytes, and intact parathyroid hormone (PTHi) were analyzed. Subsequently, the 5-D Itching Scale (5D) questionnaire, which assesses the impact of pruritus on quality of life, and the Itch Severity Scale (ISS) were administered to evaluate the intensity of pruritus.
The prevalence of pruritus in hemodialysis (HD) patients at CRER was 56%, with 112 patients experiencing it. Regarding the intensity of pruritus, assessed with the Intense Itching Scale (ISS) (Figure 1), 38.39% of patients presented very severe pruritus. Similarly, using the 5-D Itching Scale (5D) (Figure 2), the impact of pruritus on quality of life was found to be moderate in 34.82% of patients.
A strong positive correlation was observed between the two scales (r = 0.746, p < 0.001) using Pearson’s correlation, indicating that higher pruritus intensity is directly associated with lower quality of life.
Regarding the complete blood count and serum chemistry data, including electrolytes (Table 1), no direct correlation was found with itching intensity or quality of life. In contrast, when analyzing intact parathyroid hormone (PTHi) levels, values between 15–65 pg/mL were associated with mild 5-D itching, whereas levels between 301–600 pg/mL were associated with moderate 5-D itching (Table 2 and Figure 3). A chi-square test (χ² = 27.48, p = 0.025) confirmed a statistically significant association between the PTHi range and pruritus severity measured by the 5-D Itching Scale.
Pruritus affects more than half of HD patients and significantly impacts their quality of life. The ISS and 5-D Itching Scale are complementary and reliable tools for evaluating pruritus intensity and its effect on daily functioning. Moreover, elevated PTHi levels appear to be related to greater pruritus severity, underscoring the importance of biochemical monitoring and comprehensive management in this population.
